CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex
Authors
M. Abastabar
S.A.K. Afshari
+13 more
K. Ahmadikia
F. Babamahmoudi
H. Badali
P. Badiee
Z. Bandalizadeh
H. Cheraghmakani
L. Davoodi
M. Javanian
S. Khodavaisy
M. Mardani
A.A. Sepidgar
S. Seyedmousavi
T. Shokohi
Publication date
1 January 2020
Publisher
Abstract
Introduction. Limited data regarding the epidemiology and susceptibility profiles of cryptococcosis are available in the Middle East. Aim. Our study aimed to evaluate the molecular diversity, mating types and antifungal susceptibility pattern of Cryptococcus species (n=14) isolated from 320 suspected patients with cryptococcosis. Methodology. The URA5 gene was subjected to restriction fragment length polymorphism and sequence analysis. In addition, in vitro antifungal susceptibility testing was performed by Clinical and Laboratory Standards Institute (CLSI) M27-A4 and M59 guidelines. Results. Overall, 14 (4.4) patients were confirmed as cryptococcosis. Based on molecular type, 85.7 and 14.3 of the isolates were C. neoformans VN I and VN II, respectively. Phylogenetic analysis of URA5 gene sequences revealed clustering of VN I and VN II isolates into two distinct clades with a substantial difference within each molecular type. Voriconazole and 5-fluorocytosine, respectively, had the lowest (0.031 μg ml�1) and highest (8 μg ml�1) MICs. The epidemiological cutoff values (ECVs) for amphotericin B, fluconazole, voriconazole and 5-fluorocytosine encompassed �97 of all 14 C. neoformans VN I species. However, according to the CLSI document M59, ECVs for itraconazole (7; 50 of the isolates) and for posaconazole (1; 7.1 of the isolate), were one log2 dilution higher than the wild type range. Combinations of amphotericin B with 5-fluorocytosine, amphotericin B with fluconazole and fluconazole with 5-fluorocytosine exhibited synergistic effects against 37, 31 and 12.5 of the isolates, respectively. Conclusion. Our findings may significantly contribute to the development of management strategies for patients at a higher risk of cryptococcosis, particularly HIV-positive individuals. © 2020 The Author
Similar works
Full text
Available Versions
Simorgh Research Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.kmu.ac.ir:33425
Last time updated on 08/04/2021
Simorgh Research Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.kmu.ac.ir:37946
Last time updated on 14/10/2021